HK1222860A1 - 作爲葛瑞林 -酰基轉移酶抑制劑的被取代的哌啶基-乙基-嘧啶 - Google Patents

作爲葛瑞林 -酰基轉移酶抑制劑的被取代的哌啶基-乙基-嘧啶

Info

Publication number
HK1222860A1
HK1222860A1 HK16111132.8A HK16111132A HK1222860A1 HK 1222860 A1 HK1222860 A1 HK 1222860A1 HK 16111132 A HK16111132 A HK 16111132A HK 1222860 A1 HK1222860 A1 HK 1222860A1
Authority
HK
Hong Kong
Prior art keywords
ghrelin
pyrimidine
ethyl
transferase inhibitor
acyl transferase
Prior art date
Application number
HK16111132.8A
Other languages
English (en)
Chinese (zh)
Inventor
Angeles Martinez-Grau Maria
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1222860A1 publication Critical patent/HK1222860A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16111132.8A 2013-11-14 2016-09-22 作爲葛瑞林 -酰基轉移酶抑制劑的被取代的哌啶基-乙基-嘧啶 HK1222860A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382460 2013-11-14
PCT/US2014/064202 WO2015073281A1 (en) 2013-11-14 2014-11-06 Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor

Publications (1)

Publication Number Publication Date
HK1222860A1 true HK1222860A1 (zh) 2017-07-14

Family

ID=49622771

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111132.8A HK1222860A1 (zh) 2013-11-14 2016-09-22 作爲葛瑞林 -酰基轉移酶抑制劑的被取代的哌啶基-乙基-嘧啶

Country Status (40)

Country Link
US (1) US9035051B1 (hr)
EP (1) EP3068775B1 (hr)
JP (1) JP6159484B2 (hr)
KR (1) KR101739243B1 (hr)
CN (1) CN105636948B (hr)
AP (1) AP2016009189A0 (hr)
AR (1) AR098274A1 (hr)
AU (1) AU2014348967B2 (hr)
BR (1) BR112016009488B1 (hr)
CA (1) CA2926224C (hr)
CL (1) CL2016001023A1 (hr)
CR (1) CR20160184A (hr)
CY (1) CY1119489T1 (hr)
DK (1) DK3068775T3 (hr)
DO (1) DOP2016000070A (hr)
EA (1) EA028550B1 (hr)
ES (1) ES2647790T3 (hr)
HK (1) HK1222860A1 (hr)
HR (1) HRP20171648T1 (hr)
HU (1) HUE035590T2 (hr)
IL (1) IL244856A (hr)
JO (1) JO3302B1 (hr)
LT (1) LT3068775T (hr)
MA (1) MA39025B1 (hr)
ME (1) ME02841B (hr)
MX (1) MX2016006223A (hr)
NO (1) NO3068775T3 (hr)
NZ (1) NZ718373A (hr)
PE (1) PE20160609A1 (hr)
PH (1) PH12016500895A1 (hr)
PL (1) PL3068775T3 (hr)
PT (1) PT3068775T (hr)
RS (1) RS56533B1 (hr)
SG (1) SG11201602953YA (hr)
SI (1) SI3068775T1 (hr)
TN (1) TN2016000145A1 (hr)
TW (1) TWI538677B (hr)
UA (1) UA118034C2 (hr)
WO (1) WO2015073281A1 (hr)
ZA (1) ZA201602202B (hr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104672A1 (es) * 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
AR104673A1 (es) 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
EA037277B1 (ru) * 2016-08-05 2021-03-03 Бёрингер Ингельхайм Интернациональ Гмбх Производные оксадиазолопиридина для применения в качестве ингибиторов грелин-о-ацилтрасферазы (goat)
CN106478519B (zh) * 2016-10-10 2018-12-11 上海再启生物技术有限公司 一种2-甲基-4-氨基-6-氯嘧啶的制备方法
MX2020008053A (es) 2018-02-02 2020-09-07 Boehringer Ingelheim Int Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat).
SG11202006302TA (en) 2018-02-02 2020-07-29 Boehringer Ingelheim Int Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
JP7225253B2 (ja) 2018-02-02 2023-02-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンo-アシルトランスフェラーゼ(goat)阻害剤として使用するためのピラゾール置換及びインダゾール置換オキサジアゾロピリジン誘導体
PE20210175A1 (es) * 2018-02-02 2021-01-29 Boehringer Ingelheim Int Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat)
CN108610337A (zh) * 2018-05-30 2018-10-02 王丽萍 一种苯并[b]噻吩类化合物及其在肥胖和糖尿病中的应用
CN108774221A (zh) * 2018-05-30 2018-11-09 王丽萍 一种goat抑制剂及其在肥胖和糖尿病中的应用
CN108558849A (zh) * 2018-05-30 2018-09-21 王丽萍 一种苯并[b]噻吩类化合物及其在肥胖和糖尿病中的应用
CN108516971A (zh) * 2018-05-30 2018-09-11 王丽萍 一种苯并[b]噻吩类化合物及其在肥胖和糖尿病中的应用
CN108558852A (zh) * 2018-05-30 2018-09-21 王丽萍 一种goat抑制剂及其在肥胖和糖尿病中的应用
JP2023526351A (ja) 2020-05-22 2023-06-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルキル7-アミノ-5-メチル-[1,2,5]オキサジアゾロ[3,4-b]ピリジンカルボキシレートの製造方法
WO2021233884A1 (en) 2020-05-22 2021-11-25 Boehringer Ingelheim International Gmbh Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2403686C (en) * 2000-03-23 2010-01-26 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
EP1670827A2 (en) 2003-09-05 2006-06-21 Eli Lilly And Company Anti-ghrelin antibodies
KR20070034583A (ko) 2004-07-14 2007-03-28 일라이 릴리 앤드 캄파니 항-그렐린 항체
EP1814916A2 (en) 2004-11-15 2007-08-08 Eli Lilly And Company Desacyl ghrelin antibodies and therapeutic uses thereof
DE602006013937D1 (de) 2005-01-26 2010-06-10 Kistler Holding Ag Masseisolierter piezoelektrischer sensor zur messung von beschleunigung oder druck
US7479271B2 (en) 2005-02-23 2009-01-20 Eli Lilly And Company Humanized anti-ghrelin antibodies
CN101175759A (zh) * 2005-05-17 2008-05-07 先灵公司 作为治疗血脂异常的烟酸受体激动剂的杂环化合物
EP1885726B1 (en) * 2005-05-17 2016-12-14 Merck Sharp & Dohme Corp. Ortho-condensed 2-pyridinone derivatives as nicotinic acid receptor agonists for the treatment of dyslipidemia
WO2007079239A2 (en) 2005-12-30 2007-07-12 Acadia Pharmaceuticals Inc. Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof
NZ588633A (en) * 2008-03-20 2012-03-30 Forest Lab Holdings Ltd NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE
AR091516A1 (es) * 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida

Also Published As

Publication number Publication date
TN2016000145A1 (en) 2017-10-06
NZ718373A (en) 2017-12-22
AU2014348967B2 (en) 2017-05-04
NO3068775T3 (hr) 2018-02-03
KR20160068926A (ko) 2016-06-15
CA2926224C (en) 2017-05-02
JP2016537371A (ja) 2016-12-01
CY1119489T1 (el) 2018-03-07
DK3068775T3 (en) 2017-10-23
PE20160609A1 (es) 2016-07-03
US9035051B1 (en) 2015-05-19
HUE035590T2 (en) 2018-05-28
EP3068775B1 (en) 2017-09-06
JP6159484B2 (ja) 2017-07-05
CR20160184A (es) 2016-06-17
KR101739243B1 (ko) 2017-05-23
AP2016009189A0 (en) 2016-05-31
MA39025B1 (fr) 2018-05-31
ME02841B (me) 2018-01-20
JO3302B1 (ar) 2018-09-16
EA028550B1 (ru) 2017-11-30
SI3068775T1 (sl) 2017-10-30
SG11201602953YA (en) 2016-05-30
CA2926224A1 (en) 2015-05-21
TWI538677B (zh) 2016-06-21
MX2016006223A (es) 2016-08-08
AU2014348967A1 (en) 2016-04-28
LT3068775T (lt) 2017-11-27
CN105636948B (zh) 2017-10-24
UA118034C2 (uk) 2018-11-12
PL3068775T3 (pl) 2018-01-31
WO2015073281A1 (en) 2015-05-21
PH12016500895B1 (en) 2016-06-20
TW201529073A (zh) 2015-08-01
IL244856A0 (en) 2016-05-31
BR112016009488B1 (pt) 2021-01-19
CN105636948A (zh) 2016-06-01
DOP2016000070A (es) 2016-05-30
CL2016001023A1 (es) 2016-11-18
PH12016500895A1 (en) 2016-06-20
HRP20171648T1 (hr) 2017-12-15
RS56533B1 (sr) 2018-02-28
PT3068775T (pt) 2017-11-20
ES2647790T3 (es) 2017-12-26
AR098274A1 (es) 2016-05-18
ZA201602202B (en) 2019-10-30
IL244856A (en) 2017-07-31
BR112016009488A8 (pt) 2018-01-30
MA39025A1 (fr) 2017-05-31
EA201690764A1 (ru) 2016-07-29
US20150133474A1 (en) 2015-05-14
EP3068775A1 (en) 2016-09-21

Similar Documents

Publication Publication Date Title
HK1222860A1 (zh) 作爲葛瑞林 -酰基轉移酶抑制劑的被取代的哌啶基-乙基-嘧啶
HK1211578A1 (en) Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1
HK1216531A1 (zh) 新的抑制劑
HK1219104A1 (zh) 激酶抑制劑
GB201317609D0 (en) Inhibitor compounds
HK1223367A1 (zh) 新型 抑制劑
ZA201704301B (en) Microencapsulated nitrification inhibitor compositions
IL248509B (en) Nitrification inhibitor preparation sealed in a capsule
HK1222339A1 (zh) 金屬-β-內酰胺酶的抑制劑
IL240763A0 (en) The halopyrazoles as thrombin inhibitors
GB201307510D0 (en) Anchor
HK1211549A1 (en) Through anchor
EP2923896A4 (en) through anchor
HK1210748A1 (en) Through anchor
GB201305503D0 (en) Inhibitor
GB201321328D0 (en) Inhibitor compounds
GB201307906D0 (en) Corrosion inhibitor
GB201304548D0 (en) Space Anchor
GB201307155D0 (en) Kinase inhibitors